These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 8350363)

  • 41. Contralateral primary tumors in breast cancer patients in a randomized trial of adjuvant tamoxifen therapy.
    Rutqvist LE; Cedermark B; Glas U; Mattsson A; Skoog L; Somell A; Theve T; Wilking N; Askergren J; Hjalmar ML
    J Natl Cancer Inst; 1991 Sep; 83(18):1299-306. PubMed ID: 1886157
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Contralateral breast cancer and thromboembolic events in African American women treated with tamoxifen.
    McCaskill-Stevens W; Wilson J; Bryant J; Mamounas E; Garvey L; James J; Cronin W; Wickerham DL
    J Natl Cancer Inst; 2004 Dec; 96(23):1762-9. PubMed ID: 15572758
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis.
    Amir E; Seruga B; Niraula S; Carlsson L; Ocaña A
    J Natl Cancer Inst; 2011 Sep; 103(17):1299-309. PubMed ID: 21743022
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Postmastectomy radiotherapy in high-risk breast cancer patients given adjuvant systemic therapy. A 30-year long-term report from the Danish breast cancer cooperative group DBCG 82bc trial.
    Overgaard M; Nielsen HM; Tramm T; Højris I; Grantzau TL; Alsner J; Offersen BV; Overgaard J;
    Radiother Oncol; 2022 May; 170():4-13. PubMed ID: 35288227
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term cardiac morbidity and mortality in a randomized trial of pre- and postoperative radiation therapy versus surgery alone in primary breast cancer.
    Gyenes G; Rutqvist LE; Liedberg A; Fornander T
    Radiother Oncol; 1998 Aug; 48(2):185-90. PubMed ID: 9783890
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of Adjuvant Radiation Therapy Alone Versus Radiation Therapy and Endocrine Therapy in Elderly Women With Early-Stage, Hormone Receptor-Positive Breast Cancer Treated With Breast-Conserving Surgery.
    Murphy CT; Li T; Wang LS; Obeid EI; Bleicher RJ; Eastwick G; Johnson ME; Hayes SB; Weiss SE; Anderson PR
    Clin Breast Cancer; 2015 Oct; 15(5):381-9. PubMed ID: 25861716
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The effect of adjuvant tamoxifen: the latest results from the Cancer Research Campaign Adjuvant Breast Trial. Cancer Research Campaign Breast Cancer Trials Group.
    Eur J Cancer; 1992; 28A(4-5):904-7. PubMed ID: 1524921
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group.
    Morales L; Canney P; Dyczka J; Rutgers E; Coleman R; Cufer T; Welnicka-Jaskiewicz M; Nortier J; Bogaerts J; Therasse P; Paridaens R; ;
    Eur J Cancer; 2007 Jan; 43(2):331-40. PubMed ID: 17134892
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Low p27 expression predicts early relapse and death in postmenopausal hormone receptor-positive breast cancer patients receiving adjuvant tamoxifen therapy.
    Filipits M; Rudas M; Heinzl H; Jakesz R; Kubista E; Lax S; Schippinger W; Dietze O; Greil R; Stiglbauer W; Kwasny W; Nader A; Stierer M; Gnant MF;
    Clin Cancer Res; 2009 Sep; 15(18):5888-94. PubMed ID: 19723645
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII.
    Crivellari D; Bonetti M; Castiglione-Gertsch M; Gelber RD; Rudenstam CM; Thürlimann B; Price KN; Coates AS; Hürny C; Bernhard J; Lindtner J; Collins J; Senn HJ; Cavalli F; Forbes J; Gudgeon A; Simoncini E; Cortes-Funes H; Veronesi A; Fey M; Goldhirsch A
    J Clin Oncol; 2000 Apr; 18(7):1412-22. PubMed ID: 10735888
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Twelve-year mortality results of a randomized trial of 2 versus 5 years of adjuvant tamoxifen for postmenopausal early-stage breast carcinoma patients (SITAM 01).
    Belfiglio M; Valentini M; Pellegrini F; De Berardis G; Franciosi M; Rossi MC; Sacco M; Nicolucci A;
    Cancer; 2005 Dec; 104(11):2334-9. PubMed ID: 16245354
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Is tamoxifen associated with an increased risk for thromboembolic complications in patients undergoing microvascular breast reconstruction?
    Jokuszies A; Radtke C; Betzler C; Branski L; Krämer R; Vogt PM
    Ger Med Sci; 2013; 11():Doc05. PubMed ID: 23423877
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women.
    Mouridsen HT; Robert NJ
    Eur J Cancer; 2005 Aug; 41(12):1678-89. PubMed ID: 16098456
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Tamoxifen adjuvant delays early breast cancer. Results of a cooperative randomized trial].
    Delozier T; Switsers O; Génot JY; Ollivier JM; Héry M; Namer M; Frenay M; Kerbrat P; Julien JP; Naja A; Janvier M; Macé-Lesec'h J
    Bull Cancer; 1997 Jan; 84(1):25-30. PubMed ID: 9180855
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14.
    Pritchard KI; Shepherd LE; Chapman JA; Norris BD; Cantin J; Goss PE; Dent SF; Walde D; Vandenberg TA; Findlay B; O'Reilly SE; Wilson CF; Han L; Piura E; Whelan TJ; Pollak MN
    J Clin Oncol; 2011 Oct; 29(29):3869-76. PubMed ID: 21911723
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.
    Coombes RC; Hall E; Gibson LJ; Paridaens R; Jassem J; Delozier T; Jones SE; Alvarez I; Bertelli G; Ortmann O; Coates AS; Bajetta E; Dodwell D; Coleman RE; Fallowfield LJ; Mickiewicz E; Andersen J; Lønning PE; Cocconi G; Stewart A; Stuart N; Snowdon CF; Carpentieri M; Massimini G; Bliss JM; van de Velde C;
    N Engl J Med; 2004 Mar; 350(11):1081-92. PubMed ID: 15014181
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer.
    Andersson M; Storm HH; Mouridsen HT
    J Natl Cancer Inst; 1991 Jul; 83(14):1013-7. PubMed ID: 2072407
    [TBL] [Abstract][Full Text] [Related]  

  • 58. National surgical adjuvant breast and bowel project update: prevention trials and endocrine therapy of ductal carcinoma in situ.
    Vogel VG; Costantino JP; Wickerham DL; Cronin WM
    Clin Cancer Res; 2003 Jan; 9(1 Pt 2):495S-501S. PubMed ID: 12538506
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Radiotherapy-related lung fibrosis enhanced by tamoxifen.
    Bentzen SM; Skoczylas JZ; Overgaard M; Overgaard J
    J Natl Cancer Inst; 1996 Jul; 88(13):918-22. PubMed ID: 8656444
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma: a systematic review.
    Deitcher SR; Gomes MP
    Cancer; 2004 Aug; 101(3):439-49. PubMed ID: 15274057
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.